208 related articles for article (PubMed ID: 7636539)
1. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.
Wilson WH; Jamis-Dow C; Bryant G; Balis FM; Klecker RW; Bates SE; Chabner BA; Steinberg SM; Kohler DR; Wittes RE
J Clin Oncol; 1995 Aug; 13(8):1985-94. PubMed ID: 7636539
[TBL] [Abstract][Full Text] [Related]
2. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
Wilson WH; Bates SE; Fojo A; Bryant G; Zhan Z; Regis J; Wittes RE; Jaffe ES; Steinberg SM; Herdt J
J Clin Oncol; 1995 Aug; 13(8):1995-2004. PubMed ID: 7636540
[TBL] [Abstract][Full Text] [Related]
3. Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas.
Wilson WH; Bates SE; Fojo A; Chabner BA
J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R25-9. PubMed ID: 8698739
[TBL] [Abstract][Full Text] [Related]
4. Clinical reversal of multidrug resistance.
Bates SE; Wilson WH; Fojo AT; Alvarez M; Zhan Z; Regis J; Robey R; Hose C; Monks A; Kang YK; Chabner B
Stem Cells; 1996 Jan; 14(1):56-63. PubMed ID: 8820952
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
Rutherford SC; Abramson JS; Bartlett NL; Barta SK; Khan N; Joyce R; Maddocks K; Ali-Shaw T; Senese S; Yuan Y; Westin J; Leonard JP
Lancet Haematol; 2021 Nov; 8(11):e818-e827. PubMed ID: 34634256
[TBL] [Abstract][Full Text] [Related]
7. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.
Gutierrez M; Chabner BA; Pearson D; Steinberg SM; Jaffe ES; Cheson BD; Fojo A; Wilson WH
J Clin Oncol; 2000 Nov; 18(21):3633-42. PubMed ID: 11054436
[TBL] [Abstract][Full Text] [Related]
8. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
Wilson WH; Bryant G; Bates S; Fojo A; Wittes RE; Steinberg SM; Kohler DR; Jaffe ES; Herdt J; Cheson BD
J Clin Oncol; 1993 Aug; 11(8):1573-82. PubMed ID: 7687667
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
Motzer RJ; Lyn P; Fischer P; Lianes P; Ngo RL; Cordon-Cardo C; O'Brien JP
J Clin Oncol; 1995 Aug; 13(8):1958-65. PubMed ID: 7636536
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.
Miller TP; Grogan TM; Dalton WS; Spier CM; Scheper RJ; Salmon SE
J Clin Oncol; 1991 Jan; 9(1):17-24. PubMed ID: 1670642
[TBL] [Abstract][Full Text] [Related]
11. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
[TBL] [Abstract][Full Text] [Related]
13. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Wilson WH; Grossbard ML; Pittaluga S; Cole D; Pearson D; Drbohlav N; Steinberg SM; Little RF; Janik J; Gutierrez M; Raffeld M; Staudt L; Cheson BD; Longo DL; Harris N; Jaffe ES; Chabner BA; Wittes R; Balis F
Blood; 2002 Apr; 99(8):2685-93. PubMed ID: 11929754
[TBL] [Abstract][Full Text] [Related]
14. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM
Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771
[TBL] [Abstract][Full Text] [Related]
16. Randomised trial of vindesine and etoposide +/- dexverapamil in advanced non-small cell lung cancer: first results.
Gatzemeier U; Schneider A; von Pawel J
J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R17-20. PubMed ID: 8698737
[TBL] [Abstract][Full Text] [Related]
17. Clinical Reversal of Multidrug Resistance.
Bates SE; Wilson WH; Fojo AT; Alvarez M; Zhan Z; Regis J; Robey R; Hose C; Monks A; Kang YK; Chabner B
Oncologist; 1996; 1(4):269-275. PubMed ID: 10388001
[TBL] [Abstract][Full Text] [Related]
18. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
19. Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy.
Floeter AE; Patel A; Tran M; Chamberlain MC; Hendrie PC; Gopal AK; Cassaday RD
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):225-230. PubMed ID: 28169156
[TBL] [Abstract][Full Text] [Related]
20. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
